GW Henssler & Associates Ltd. Has $2.81 Million Position in Aetna Inc. (AET)

GW Henssler & Associates Ltd. reduced its stake in shares of Aetna Inc. (NYSE:AET) by 9.9% during the second quarter, Holdings Channel reports. The institutional investor owned 18,476 shares of the company’s stock after selling 2,034 shares during the period. GW Henssler & Associates Ltd.’s holdings in Aetna were worth $2,805,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of AET. Guardian Life Insurance Co. of America boosted its stake in Aetna by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 1,353 shares of the company’s stock valued at $173,000 after buying an additional 9 shares in the last quarter. Concert Wealth Management Inc. boosted its position in shares of Aetna by 0.4% in the first quarter. Concert Wealth Management Inc. now owns 3,262 shares of the company’s stock valued at $405,000 after buying an additional 14 shares during the period. CAPROCK Group Inc. boosted its position in shares of Aetna by 0.9% in the first quarter. CAPROCK Group Inc. now owns 2,824 shares of the company’s stock valued at $360,000 after buying an additional 25 shares during the period. Rehmann Capital Advisory Group boosted its position in shares of Aetna by 1.1% in the first quarter. Rehmann Capital Advisory Group now owns 2,335 shares of the company’s stock valued at $298,000 after buying an additional 25 shares during the period. Finally, Geneva Advisors LLC boosted its position in shares of Aetna by 1.0% in the first quarter. Geneva Advisors LLC now owns 2,588 shares of the company’s stock valued at $330,000 after buying an additional 25 shares during the period. Hedge funds and other institutional investors own 91.69% of the company’s stock.

Shares of Aetna Inc. (NYSE:AET) opened at 155.90 on Thursday. Aetna Inc. has a 52-week low of $104.59 and a 52-week high of $161.69. The company’s 50 day moving average is $154.63 and its 200 day moving average is $139.99. The firm has a market cap of $51.77 billion, a price-to-earnings ratio of 34.61 and a beta of 0.54.

Aetna (NYSE:AET) last issued its quarterly earnings results on Thursday, August 3rd. The company reported $3.42 EPS for the quarter, topping the Zacks’ consensus estimate of $2.34 by $1.08. The firm had revenue of $15.52 billion for the quarter, compared to analyst estimates of $15.34 billion. Aetna had a net margin of 2.52% and a return on equity of 20.52%. The business’s revenue for the quarter was down 2.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.21 EPS. Analysts anticipate that Aetna Inc. will post $9.55 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Friday, July 28th. Stockholders of record on Thursday, July 13th were paid a $0.50 dividend. The ex-dividend date of this dividend was Tuesday, July 11th. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.28%. Aetna’s dividend payout ratio (DPR) is 43.67%.

TRADEMARK VIOLATION NOTICE: “GW Henssler & Associates Ltd. Has $2.81 Million Position in Aetna Inc. (AET)” was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this report on another site, it was stolen and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://sportsperspectives.com/2017/08/17/gw-henssler-associates-ltd-has-2-81-million-position-in-aetna-inc-aet.html.

Several equities research analysts have recently weighed in on the company. Royal Bank Of Canada reissued a “buy” rating and set a $145.00 price objective on shares of Aetna in a research note on Monday, April 24th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $150.00 target price (up previously from $140.00) on shares of Aetna in a research report on Wednesday, May 3rd. Stifel Nicolaus reaffirmed a “buy” rating and issued a $150.00 target price (up previously from $130.00) on shares of Aetna in a research report on Wednesday, May 3rd. Jefferies Group LLC reissued a “hold” rating and set a $140.00 price objective (up previously from $133.00) on shares of Aetna in a research report on Wednesday, May 3rd. Finally, Cleveland Research raised Aetna from a “neutral” rating to a “buy” rating in a research report on Thursday, May 11th. Eight investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $157.09.

In other Aetna news, EVP Margaret M. Mccarthy sold 27,028 shares of the stock in a transaction on Wednesday, June 7th. The shares were sold at an average price of $149.23, for a total transaction of $4,033,388.44. Following the completion of the sale, the executive vice president now owns 33,563 shares of the company’s stock, valued at approximately $5,008,606.49. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.90% of the stock is currently owned by corporate insiders.

Aetna Company Profile

Aetna Inc is a diversified healthcare benefits company. The Company operates through three segments: Health Care, Group Insurance and Large Case Pensions. It offers a range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental, behavioral health, group life and disability plans, medical management capabilities, Medicaid healthcare management services, Medicare Advantage and Medicare Supplement plans, workers’ compensation administrative services and health information technology (HIT) products and services.

Want to see what other hedge funds are holding AET? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aetna Inc. (NYSE:AET).

Institutional Ownership by Quarter for Aetna (NYSE:AET)

Receive News & Ratings for Aetna Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aetna Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply